#1 Clinical Trials Search in Europe

Study on Rezpegaldesleukin for Treating Moderate-to-Severe Atopic Dermatitis in Adults

2 1

What is this study about?

This clinical trial is focused on studying atopic dermatitis, a condition that causes the skin to become red, itchy, and inflamed. The study will evaluate a treatment called rezpegaldesleukin, also known by its code name NKTR-358. This treatment is given as a solution for injection under the skin. The trial will also use a placebo for comparison purposes.

The purpose of the study is to assess how effective and safe rezpegaldesleukin is for adults with moderate-to-severe atopic dermatitis. Participants in the study will receive either the treatment or a placebo over a period of 54 weeks. The study will monitor changes in the severity of the skin condition and any side effects that may occur.

Throughout the study, participants will have regular check-ups to track their progress and any changes in their condition. The study aims to provide valuable information on whether rezpegaldesleukin can be a beneficial treatment option for those suffering from moderate-to-severe atopic dermatitis.

1 Initial Visit and Randomization

Upon joining the study, the patient will attend an initial visit where eligibility is confirmed. This includes a diagnosis of atopic dermatitis for at least 12 months and meeting specific severity criteria.

The patient will be randomly assigned to receive either the study medication, rezpegaldesleukin, or a placebo. This process is double-blind, meaning neither the patient nor the study team will know which treatment is being administered.

2 Treatment Phase

The patient will receive rezpegaldesleukin or placebo through a subcutaneous injection. The medication is administered as a solution for injection.

The treatment will continue for a total of 54 weeks, with regular administration as per the study protocol.

3 Monitoring and Assessments

Throughout the study, the patient will undergo regular assessments to monitor the effectiveness and safety of the treatment. This includes measuring changes in the severity of atopic dermatitis using various scales such as EASI (Eczema Area and Severity Index) and vIGA-AD (Investigator’s Global Assessment for Atopic Dermatitis).

The patient will also be monitored for any adverse events or side effects that may occur during the study period.

4 Follow-Up

After completing the treatment phase, the patient will have follow-up visits to assess the long-term effects of the treatment and to ensure any side effects are managed appropriately.

The study aims to evaluate the mean percent change in EASI from baseline at Week 16 and other secondary outcomes over the 54-week period.

Who Can Join the Study?

  • Provide written, informed consent to participate in the study and agree to follow the study procedures.
  • Agree to use highly effective contraceptives during the study.
  • Be a male or female between 18 and 70 years old on the day of signing the consent form. In some places, the legal age of consent might be higher than 18.
  • Have a diagnosis of Atopic Dermatitis (AD) for at least 12 months before the first screening visit. AD is a skin condition that causes itchy and inflamed skin.
  • Meet the following AD severity criteria:
    • EASI score of 16 or higher at both screening and randomization visits. EASI is a tool used to measure the severity of eczema.
    • vIGA-AD score of 3 or higher at both screening and randomization visits. vIGA-AD is a scale used to assess the overall severity of AD.
    • At least 10% of the body surface area (BSA) affected by AD at both screening and randomization visits.
  • Be a candidate for systemic therapy, which means treatment that affects the entire body, and have a history of not responding well to topical medications (creams or ointments applied to the skin) within 6 months before the first screening visit.
  • Have a history of not achieving good disease control with topical medications, defined as mild disease or better, after using at least a medium potency topical corticosteroid (TCS) for at least 4 weeks or the maximum recommended duration.
  • Have a history of significant adverse reactions to TCS, such as skin thinning, allergic reactions, or effects on the whole body, that make further treatment not advisable according to the study doctor.

Who Cannot Join the Study?

  • Patients who have previously used biologic treatments for their condition cannot participate.
  • Patients with other skin conditions that might interfere with the study results are not eligible.
  • Patients with a history of severe allergic reactions to similar medications are excluded.
  • Patients with certain infections or diseases that could affect the study are not allowed to join.
  • Pregnant or breastfeeding women cannot take part in the study.
  • Patients who are currently participating in another clinical trial are not eligible.
  • Patients with a history of drug or alcohol abuse may be excluded.
  • Patients with certain medical conditions that could interfere with the study results are not eligible.
  • Patients who are unable to follow the study procedures or attend study visits are excluded.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Diamond Clinic Sp. z o.o. Cracow Poland
Center For Pediatric And Adolescent Medicine Of The Johannes Gutenberg University Mainz Mainz Germany
Hautarztpraxis Dr. Mihaescu Augsburg Germany
Alergo Med Osrodek Badan Klinicznych Sp. z o.o. Tarnow Poland
Royalderm Agnieszka Nawrocka Warsaw Poland
Dermoklinika – Centrum Medyczne s.c. M. Kierstan J. Narbutt A. Lesiak Lodz Poland

Other Sites

Site Name City Country Status
SYNEXUS Magyarorszag Kft. Budapest Hungary
Dkc Fokus-5 Lzip OOD Sofia Bulgaria
Mrjoaaenz Ifsonruusq Cbjumyog Scmzatoc Scy z okhl Warsaw Poland
Mxhurgw Cxdpej Hdss Emnx Sofia Bulgaria
Cstrpwefjk Pjfyumkopxa Lztajzirskxrwneeqdbfrdm Mullrnkd sftlv Wroclaw Poland
Dirmjrhoaqxkvqxeezhpthv czfzjf “jctskhchhisorix Ecsy Sofia Bulgaria
Usdkxepmtsbvgswmoaioh Ecqcgkvn Arl Erlangen Germany
Cupiqox Updpsksdxdjwgzscfgml Bamqjo Kqv Berlin Germany
Frqsweju Nudyrpccz Kscwheajl Vrddzetou Prague Czechia
Kgatbpfm dzl Uyndhsxhbvmw Mokbxbbr Aid Munich Germany
Ugmhcjrzcalp Llirdwo Leipzig Germany
Pnuizcacxew Sjbofx difbwn Zagreb Croatia
Uxvomaubnujxdwmfvokas Srskiavfatsrcbqvgi Amj Kiel Germany
Comwber Bbeta Kngswemaqrd Pdwpsatk Smw z ojkm Gdansk Poland
Hoqksvco Urjznxghgstbm Vnefkm Du Lws Niobvb Granada Spain
Kqfxmly Afzxgzzmv Sde z oahk Warsaw Poland
Ctcsesy Ncdfmewrwnlr Tnehfjs Drnjf Lvumeq Sni z onct Cracow Poland
Mmyfeoe Cvrooy Mwgeygvvlw Popymw Oel Pleven Bulgaria
Klq Zqqqag Zagreb Croatia
Ujqskzmssxjnu Snzwuzc Klljjrpip Ijdynaxtegxv Ctbuyhb W Rwyvjotln Rzeszow Poland
Mbdeswt Cmzqdt Eunjwsusu Onl Sofia Bulgaria
Pxmysdwaar shmltv Prague Czechia
Ukfabm Mqfvxoq Cuovlj Eplu Plovdiv Bulgaria
Dgrgzcrgxw Agc Ckkapjortb Cajxdc Xdynilcpaldu Etfc Sofia Bulgaria
Oaabnqn Bvtvf Kfbixrepaag Bb Rhcazize Sqo z oral Ilawa Poland
Plgmwd Pnjgwzuik akvv Pardubice Czechia
Sunuldo Prmtou Svp z opxi Poznan Poland
Pkizseaxj Iyxbevuh Mkkeceeu Mjygxywhsvhy Sojzz Wxjdpocyiohj I Ajgimojncqxld Warsaw Poland
Pwmoso Sqol Skorzewo Poland
Gdsese Uahwjbrluv Fubwmsrle Frankfurt Germany
Dinumtbixq Scs z oydz Wroclaw Poland
Uhfkfuydhmregexhbxzcx Aqinrdin Augsburg Germany
Wsrhpwmzd I Bvnevrwi A Szoqnhmestvk sqyi Wroclaw Poland
Thvwa Puzrrojziqj Spdxpsqfvnbf Cdkyaux Mqnzdwmr Ssc z oili Szczecin Poland
Trtqskcheya ult Scstktjuwki Bjrbqeqs Gcpe Bad Bentheim Germany
Poxnif Behw sxeszp Brno-Stred Czechia
Cwpvivdw Rnrwlqpv Gbgtn Sol z oyxd Warsaw Poland
Rmirxyxcn Rmndbkxm Gupg Darmstadt Germany
Cfcdbpv Modvmysj Awdhcxe Bolutax Kmkdwjxok Cracow Poland
Iyd Idbhxsrynhfighnav Szokz Anesjdenkef Gssi Berlin Germany
Aklzbknqy Mrujrbo Cefzas Oag Dupnitsa Bulgaria
Nvifdkbu sfcygkamkv bvbimfd zw mrcigyvwgn rjrkdkyatijkqj Ivanic-Grad Croatia
Eql Incvzqva Mkrwssir Sogf Poznan Poland

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Bulgaria Bulgaria
Not recruiting
30.04.2024
Croatia Croatia
Not recruiting
30.04.2024
Czechia Czechia
Not recruiting
30.04.2024
Germany Germany
Not recruiting
30.04.2024
Hungary Hungary
Not recruiting
30.04.2024
Poland Poland
Not recruiting
30.04.2024
Spain Spain
Not recruiting
30.04.2024

Trial locations

Investigated Drugs:

Rezpegaldesleukin is a medication being studied for its effectiveness and safety in treating adults with moderate-to-severe atopic dermatitis, a type of skin condition. The trial aims to see how well this medication works in reducing the symptoms of the condition compared to not receiving the active treatment. Rezpegaldesleukin is being tested to understand its potential benefits for patients who have not previously been treated with biologic therapies.

Investigated Diseases:

Atopic Dermatitis – Atopic Dermatitis is a chronic skin condition characterized by dry, itchy, and inflamed skin. It often begins in childhood but can occur at any age. The disease tends to flare periodically and then subside. It is associated with a malfunction in the skin barrier, leading to increased sensitivity and susceptibility to irritants and allergens. The condition can cause significant discomfort and may affect sleep and quality of life. Environmental factors, stress, and genetic predisposition can influence its progression.

Trial ID:
2023-507456-69-00
Protocol code:
23-358-05
NCT ID:
NCT06136741
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • Long-Term Safety and Efficacy of Lebrikizumab in Children and Adolescents With Moderate-to-Severe Atopic Dermatitis

    Recruiting

    3 1
    Investigated Diseases:
    Investigated Drugs:
    Czechia France Germany Poland Spain

  • A study to evaluate the safety and effectiveness of galvokimig in adults with moderate to severe atopic dermatitis

    Recruiting

    2 1
    Investigated Diseases:
    Bulgaria Czechia Germany Hungary Poland